Author

X. Yang

Observed name: Xiaoxu Yang

Institution: Harbin Medical University

Observed institutions: Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Hunan Cancer Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, CSPC Pharmaceutical Group, Xi'an Jiaotong University

ORCID: 0009-0004-5337-0766

Observed ORCID: 0009-0004-5337-0766

OpenAlex ID: A5121094599

Dissecting glioblastoma risk signatures in the tumor immune microenvironment based on multi-dimensional transcriptomics

2026 · Tengyue Li, Wanqi Mi, et al. · GigaScience

1051P Thalidomide for prevention of camrelizumab-induced RCCEP in advanced NSCLC: A multicenter real-world study

2025 · Z. Ming, X. Yang, et al. · Annals of Oncology

250eP The efficacy and safety of fruquintinib(F) plus FOLFIRI as second-line(2L) treatment in bevacizumab(Bev)-pretreated RAS-mutated (RAS-m) metastatic colorectal cancer(mCRC)

2025 · X. Yang, Z. Liu, et al. · Annals of Oncology

989P Glumetinib plus albumin-bound docetaxel (HB1801) in patients with MET overexpression, actionable genetic alteration- (AGA-) negative non-small cell lung cancer (Gleam Study)

2025 · Y. Yu, S. Lu, et al. · Annals of Oncology

676MO Neoadjuvant chemo-immunotherapy with camrelizumab plus chemotherapy in resectable or potentially resectable locally advanced head and neck squamous cell carcinoma: an open-label, single-arm, phase II trial

2025 · S. Miao, X. Mao, et al. · Annals of Oncology

Works count: 5

Citation count:

H-index:

I10-index: